Genetic and immunologic characteristics of colorectal cancer patients with KRAS mutations and predictive significance of tumor immune microenvironment in adjuvant chemotherapy

作     者：Zhengqi Wen Wenliang Li Chengmin Shi Junrui Ma Sihui Zhao Ruize Zhou Xihong Liu Rong Yang Zhiping Zhang Hushan Zhang Bo Li Zhengqi Wen;Wenliang Li;Chengmin Shi;Junrui Ma;Sihui Zhao;Ruize Zhou;Xihong Liu;Rong Yang;Zhiping Zhang;Hushan Zhang;Bo Li

作者机构：Department of OncologyThe First Affiliated Hospital of Kunming Medical UniversityKunmingYunnan 650032China The Third Affliated Hospital of Kunming Medical University(Yunnan Cancer Center)KunmingYunnan 650021China Gastrointestinal and Hernia SurgeryThe First Affiliated Hospital of Kunming Medical UniversityKunmingYunnan 650032China School of NursingYunnan University of Chinese MedicineKunmingYunnan 650022China Department of General SurgeryThe First People's Hospital of Yunnan ProvinceKunmingYunnan 650000China Department of General SurgeryThe Affiliated Hospital of Yunnan UniversityYunnan 650011China Medical Department3D Medicines Inc.Shanghai 201114China Zhaotong Health Vocational CollegeZhaotongYunnan 657000China 

出 版 物：《Genes & Diseases》 (基因与疾病（英文）)

年 卷 期：2024年第11卷第3期

页      面：43-46页

核心收录：

学科分类：0710[理学-生物学] 1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by the National Natural Science Foundation of China(No.81960100 81760511) 

主　　题：KRAS colorectal patients 

摘      要：Colorectal cancer(CRC)is one of the most common cancers around the world,and it is one of the leading causes of cancer-related death.1 Although anti-EGFR therapy and immune checkpoint inhibitor(ICl)therapy are becoming more and more important for colorectal therapy,however,clinical outcomes of current treatments for metastatic CRC,especially with ICls,have been shown to be affected by the status of ***,KRAS mutation status detection has become a very important diagnostic factor for managing metastatic CRC patients.